AIMS: We examined the cost-effectiveness of extended smoking cessation treatment in older smokers. DESIGN:Participants who completed a 12-week smoking cessation program were factorial randomized to extended cognitive behavioral treatment and extended nicotine replacement therapy. SETTING: A free-standing smoking cessation clinic. PARTICIPANTS: A total of 402 smokers aged 50 years and older were recruited from the community. MEASUREMENTS: The trial measured biochemically verified abstinence from cigarettes after 2 years and the quantity of smoking cessation services utilized. Trial findings were combined with literature on changes in smoking status and the age- and gender-adjusted effect of smoking on health-care cost, mortality and quality of life over the long term in a Markov model of cost-effectiveness over a lifetime horizon. FINDINGS: The addition of extended cognitive behavioral therapy added $83 in smoking cessation services cost [P = 0.012, confidence interval (CI) = $22-212]. At the end of follow-up, cigarette abstinence rates were 50.0% with extended cognitive behavioral therapy and 37.2% without this therapy (P < 0.05, odds ratio 1.69, CI 1.18-2.54). The model-based incremental cost-effectiveness ratio was $6324 per quality-adjusted life year (QALY). Probabilistic sensitivity analysis found that the additional $947 in lifetime cost of the intervention had a 95% confidence interval of -$331 to 2081; the 0.15 additional QALYs had a confidence interval of 0.035-0.280, and that the intervention was cost-effective against a $50 000/QALY acceptance criterion in 99.6% of the replicates. Extended nicotine replacement therapy was not cost-effective. CONCLUSIONS: Adding extended cognitive behavior therapy to standard cessation treatment was cost-effective. Further intensification of treatment may be warranted.
RCT Entities:
AIMS: We examined the cost-effectiveness of extended smoking cessation treatment in older smokers. DESIGN:Participants who completed a 12-week smoking cessation program were factorial randomized to extended cognitive behavioral treatment and extended nicotine replacement therapy. SETTING: A free-standing smoking cessation clinic. PARTICIPANTS: A total of 402 smokers aged 50 years and older were recruited from the community. MEASUREMENTS: The trial measured biochemically verified abstinence from cigarettes after 2 years and the quantity of smoking cessation services utilized. Trial findings were combined with literature on changes in smoking status and the age- and gender-adjusted effect of smoking on health-care cost, mortality and quality of life over the long term in a Markov model of cost-effectiveness over a lifetime horizon. FINDINGS: The addition of extended cognitive behavioral therapy added $83 in smoking cessation services cost [P = 0.012, confidence interval (CI) = $22-212]. At the end of follow-up, cigarette abstinence rates were 50.0% with extended cognitive behavioral therapy and 37.2% without this therapy (P < 0.05, odds ratio 1.69, CI 1.18-2.54). The model-based incremental cost-effectiveness ratio was $6324 per quality-adjusted life year (QALY). Probabilistic sensitivity analysis found that the additional $947 in lifetime cost of the intervention had a 95% confidence interval of -$331 to 2081; the 0.15 additional QALYs had a confidence interval of 0.035-0.280, and that the intervention was cost-effective against a $50 000/QALY acceptance criterion in 99.6% of the replicates. Extended nicotine replacement therapy was not cost-effective. CONCLUSIONS: Adding extended cognitive behavior therapy to standard cessation treatment was cost-effective. Further intensification of treatment may be warranted.
Authors: Fujian Song; James Raftery; Paul Aveyard; Chris Hyde; Pelham Barton; Nerys Woolacott Journal: Med Decis Making Date: 2002 Sep-Oct Impact factor: 2.583
Authors: N F Woolacott; L Jones; C A Forbes; L C Mather; A J Sowden; F J Song; J P Raftery; P N Aveyard; C J Hyde; P M Barton Journal: Health Technol Assess Date: 2002 Impact factor: 4.014
Authors: A Z LaCroix; J Lang; P Scherr; R B Wallace; J Cornoni-Huntley; L Berkman; J D Curb; D Evans; C H Hennekens Journal: N Engl J Med Date: 1991-06-06 Impact factor: 91.245
Authors: Sharon M Hall; Gary L Humfleet; Ricardo F Muñoz; Victor I Reus; Julie A Robbins; Judith J Prochaska Journal: Addiction Date: 2009-04-09 Impact factor: 6.526
Authors: Brian Chen; Gerard A Silvestri; Jennifer Dahne; Kyueun Lee; Matthew J Carpenter Journal: J Gen Intern Med Date: 2022-01-28 Impact factor: 6.473
Authors: Viengneesee Thao; John A Nyman; David B Nelson; Anne M Joseph; Barbara Clothier; Patrick J Hammett; Steven S Fu Journal: Addiction Date: 2019-09-04 Impact factor: 6.526
Authors: Anne M Joseph; Alexander J Rothman; Daniel Almirall; Abbie Begnaud; Caroline Chiles; Paul M Cinciripini; Steven S Fu; Amanda L Graham; Bruce R Lindgren; Anne C Melzer; Jamie S Ostroff; Elizabeth L Seaman; Kathryn L Taylor; Benjamin A Toll; Steven B Zeliadt; David M Vock Journal: Am J Respir Crit Care Med Date: 2018-01-15 Impact factor: 30.528